Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
bluebird bio (BLUE) was a biotechnology company focused on gene therapies for severe genetic diseases until its acquisition by Carlyle and SK Capital Partners in June 2025. The acquisition resulted in the company's delisting from NASDAQ, ending its existence as a publicly traded entity. Shareholders received either $3.00 per share plus contingent value rights or $5.00 per share in cash in a transaction valued at approximately $29 million.
The sale followed significant financial challenges including cash constraints, workforce reductions of 25%, and going-concern warnings. The company had struggled to achieve commercial success with its three FDA-approved gene therapies despite being among the first to bring cell-based gene therapies to market. Competition in the sickle cell disease market, slower-than-expected patient uptake, reimbursement challenges related to multi-million dollar price tags, and safety concerns contributed to the financial pressure that led to the strategic sale.
Under new private ownership, the company rebranded as Genetix Biotherapeutics and continues commercializing its approved therapies: Zynteglo for beta-thalassemia, Lyfgenia for sickle cell disease, and Skysona for cerebral adrenoleukodystrophy. News related to bluebird bio may cover topics including gene therapy market trends, regulatory updates on approved therapies, safety monitoring results, patient access and reimbursement developments, competition in rare disease treatments, and the evolution of the commercial gene therapy industry.
bluebird bio, Inc. (Nasdaq: BLUE) will discuss its first quarter 2024 results and business updates on May 9 at 8:00 a.m. ET. The company will also participate in investor conferences on May 16 and June 12. Investors can access the live webcasts on bluebird bio's website.
bluebird bio, Inc. announced the completion of the first commercial cell collection for LYFGENIA gene therapy, a one-time treatment for sickle cell disease. LYFGENIA was FDA-approved in December 2023 and is the most extensively studied gene therapy for the disease. The cells were collected at Children’s National Hospital in Washington, DC, marking a significant milestone in the treatment of sickle cell disease.
FAQ
What is the current stock price of Bluebird Bio (BLUE)?
What is the market cap of Bluebird Bio (BLUE)?
